The Rise of High-Potency Intermediates(HPIs): Manufacturing Challenges and Control

In the field of pharmaceutical manufacturing, we all know that what truly determines a company’s capabilities is often not the number of products listed in its catalog, but whether its system can still operate stably when project complexity truly increases.

In recent years, more and more clients have explicitly mentioned a key term at the beginning of their projects: High-Potency Intermediates.

This is not just a conceptual hype, but a direct result of changes in the global innovative drug development path. From targeted small molecules for cancer to ADC-related structures, from hormonal compounds to immunomodulatory drugs, high-potency characteristics are shifting to the intermediate stage. This poses a challenge to manufacturers that goes beyond simply “can we do it,” but rather whether they possess the systemic capacity to handle it.

The Growth of High-Potency Intermediates Stems from Real R&D Needs

Based on the projects we have actually worked on, the increase in demand for high-potency intermediates is mainly concentrated in the following areas:

• Small molecule targeted drugs and their key intermediates in the oncology field
• ADC/XDC drug-related linker and payload precursor structures
• Low-dose, high-efficacy hormonal and immunomodulatory molecules

These projects have one thing in common:

The annual usage is not large, but the requirements for exposure control, impurity management, and process stability are extremely high.

According to the global oncology R&D trend report released by IQVIA, oncology pipelines have long occupied a central position in drug development, and a considerable number of candidate molecules are explicitly classified as high-potency compounds. This means that high potency is no longer just an issue at the API or formulation stage, but needs to be systematically managed starting from the intermediate stage.

High-Potency Intermediates Test “Systemic Capabilities,” Not Just Single-Point Technology

In actual collaborations, we often find a misconception:

High-potency intermediates are simply understood as “ordinary intermediates + stricter operations.”

In fact, the differences between the two are far more significant.

1. Route design must be based on exposure control

In high-potency projects, route selection is no longer solely focused on yield and the number of steps, but prioritizes:

• Whether there are unavoidable open operations
• Whether powder transfer can be avoided
• Whether key steps can be completed through solution-phase or closed systems

Many routes that are feasible at the laboratory stage are directly rejected during scale-up evaluation due to exposure risks. Therefore, truly sustainable high-potency projects often incorporate engineering and safety logic from the route design stage.

2. Impurity Control Upgraded from “Quality Problem” to “Risk Management Problem”

Highly active molecules usually have specific biological targets, which means that structurally similar impurities often also possess biological activity.

In these types of projects:

• Potential genotoxic impurities (PGIs) need to be systematically evaluated at the intermediate stage.
• The formation mechanism and removal logic of impurities must be designed upfront.
• Risks cannot simply be postponed to the API or formulation stage.

This is why high-quality clients repeatedly inquire about the impurity pathways at the intermediate stage during audits, rather than just focusing on the final test results.

The Real Challenge: Is it “Reproducible in the Long Term”?

From industry experience, the reasons for failure in highly active intermediate projects are rarely due to “inability to perform the chemistry,” but rather concentrated in the following areas:

• The process works in one or two production runs, but cannot be stably replicated.
• Uncontrollable risks are exposed during deviation handling.
• Cleaning validation is difficult to consistently pass under real production conditions.

The EMA clearly states in its guidance on Health-Based Exposure Limits (HBEL):

The effectiveness of exposure control must be continuously verified under real production conditions, not just at the documentation level.

This is why highly active projects often quickly amplify a manufacturing company’s shortcomings in equipment, processes, training, and management.

Small-Volume Projects Often Carry High Strategic Value

From a business perspective, highly active intermediates have distinct characteristics:

• Limited annual demand for a single product
• But highly critical to the client’s pipeline progress
• Supply stability is far more important than price fluctuations

For pharmaceutical companies, highly active intermediates are not ordinary procurement projects, but rather guarantee nodes for R&D continuity.

For manufacturers, these types of projects are not suitable for measuring value using “tonnage logic.” The true competitive advantage comes from:

• Whether they possess the ability to operate compliantly in the long term
• Whether they can maintain quality consistency under complex conditions
• Whether they can become a reliable technical partner for clients at critical stages

Highly Active Intermediates: An Amplified Test of a Manufacturer’s “True Capabilities”

Highly active intermediates are not a marketing label, but a magnifying glass. It will clearly highlight:

• Whether the process design truly understands the risks;
• Whether the quality system can withstand in-depth audits;
• Whether the team possesses the capabilities for long-term execution and improvement.

Against the backdrop of innovative drugs continuously developing towards higher efficiency and precision, The Rise of High-Potency Intermediates is not a trend prediction, but a reality that is already happening.

Conclusion: We Provide Not Just Intermediates, But Sustainable Manufacturing Solutions

At Tianming Pharmaceuticals, we have always believed that the core value of high-potency intermediate projects lies not in “completing a single delivery,” but in whether it can support our clients in advancing their product lifecycle in a long-term, compliant, and stable manner.

From route design and risk assessment to large-scale production, we focus more on:

Whether this route is truly suitable for industrial implementation.

If you are working on an intermediate or API project involving high-potency structures and hope to achieve a truly feasible balance between safety, quality, and schedule, please feel free to contact us.